Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 75

1.

The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis.

Schubert M, Joniau S, Gontero P, Kneitz S, Scholz CJ, Kneitz B, Briganti A, Karnes RJ, Tombal B, Walz J, Hsu CY, Marchioro G, Bader P, Bangma C, Frohneberg D, Graefen M, Schröder F, van Cangh P, van Poppel H, Spahn M.

Adv Urol. 2012;2012:612707. doi: 10.1155/2012/612707. Epub 2012 Jan 31.

PMID:
22400018
[PubMed]
Free PMC Article
2.

Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin.

Leibovich BC, Engen DE, Patterson DE, Pisansky TM, Alexander EE, Blute ML, Bergstralh EJ, Zincke H.

J Urol. 2000 Apr;163(4):1178-82.

PMID:
10737490
[PubMed - indexed for MEDLINE]
3.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
[PubMed - indexed for MEDLINE]
4.

Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study.

Cookson MS, Sogani PC, Russo P, Sheinfeld J, Herr H, Dalbagni G, Reuter VE, Begg CB, Fair WR.

Br J Urol. 1997 Mar;79(3):432-8.

PMID:
9117227
[PubMed - indexed for MEDLINE]
5.

Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Allen Z, Adamovich E.

Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):32-43.

PMID:
15629591
[PubMed - indexed for MEDLINE]
6.

Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer.

Zeliadt SB, Potosky AL, Penson DF, Etzioni R.

Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):395-402. Epub 2006 Aug 14.

PMID:
16904843
[PubMed - indexed for MEDLINE]
7.

Optimal duration of androgen deprivation in combination with radiation therapy for Japanese men with high-risk prostate cancer.

Takaha N, Okihara K, Kamoi K, Kimura Y, Yamada T, Kawauchi A, Kobayashi K, Yamazaki H, Nishimura T, Miki T.

Urol Int. 2011;87(1):28-34. doi: 10.1159/000324478. Epub 2011 Jun 23.

PMID:
21701133
[PubMed - indexed for MEDLINE]
8.

The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.

Fair WR, Cookson MS, Stroumbakis N, Cohen D, Aprikian AG, Wang Y, Russo P, Soloway SM, Sogani P, Sheinfeld J, Herr H, Dalgabni G, Begg CB, Heston WD, Reuter VE.

Urology. 1997 Mar;49(3A Suppl):46-55.

PMID:
9123736
[PubMed - indexed for MEDLINE]
9.

Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.

Gjertson CK, Asher KP, Sclar JD, Goluboff ET, Olsson CA, Benson MC, McKiernan JM.

Urology. 2007 Oct;70(4):723-7.

PMID:
17991544
[PubMed - indexed for MEDLINE]
10.

Impact of adjuvant androgen-deprivation therapy on disease progression in patients with node-positive prostate cancer.

Park S, Kim SC, Kim W, Song C, Ahn H.

Korean J Urol. 2011 Nov;52(11):741-5. doi: 10.4111/kju.2011.52.11.741. Epub 2011 Nov 17.

PMID:
22195262
[PubMed]
Free PMC Article
11.

Long-term effects of androgen deprivation therapy in prostate cancer patients.

Basaria S, Lieb J 2nd, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS.

Clin Endocrinol (Oxf). 2002 Jun;56(6):779-86.

PMID:
12072048
[PubMed - indexed for MEDLINE]
12.

Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.

Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML.

J Urol. 2008 May;179(5):1830-7; discussion 1837. doi: 10.1016/j.juro.2008.01.022. Epub 2008 Mar 18.

PMID:
18353378
[PubMed - indexed for MEDLINE]
13.

Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E.

Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):669-77. Epub 2006 May 6.

PMID:
16682149
[PubMed - indexed for MEDLINE]
14.

Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.

Stenmark MH, Blas K, Halverson S, Sandler HM, Feng FY, Hamstra DA.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e335-44. doi: 10.1016/j.ijrobp.2011.04.037. Epub 2011 Jun 7.

PMID:
21645976
[PubMed - indexed for MEDLINE]
15.

[Radical prostatectomy for high-risk prostate cancer].

Arai Y, Kawamorita N, Kaiho Y, Ishidoya S.

Gan To Kagaku Ryoho. 2011 Feb;38(2):193-6. Japanese.

PMID:
21368483
[PubMed - indexed for MEDLINE]
16.

Role of androgen deprivation therapy for node-positive prostate cancer.

Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K.

J Clin Oncol. 2009 Jan 1;27(1):100-5. doi: 10.1200/JCO.2007.14.2042. Epub 2008 Dec 1.

PMID:
19047295
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Risk of prostate carcinoma death in patients with lymph node metastasis.

Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG.

Cancer. 2001 Jan 1;91(1):66-73.

PMID:
11148561
[PubMed - indexed for MEDLINE]
18.

Surgical management of lymph-node-positive prostate cancer: improves symptomatic control.

Wiegand LR, Hernandez M, Pisters LL, Spiess PE.

BJU Int. 2011 Apr;107(8):1238-42. doi: 10.1111/j.1464-410X.2010.09657.x. Epub 2010 Sep 29.

PMID:
20880197
[PubMed - indexed for MEDLINE]
19.

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.

Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S.

J Clin Oncol. 2006 Aug 20;24(24):3979-83.

PMID:
16921050
[PubMed - indexed for MEDLINE]
Free Article
20.

Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.

Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS.

Cancer. 2006 Feb 1;106(3):581-8.

PMID:
16388523
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk